Preprint · OA
via OpenAlex
Proteostasis and Movement Disorders: Parkinson's Disease and Amyotrophic Lateral Sclerosis
Daryl A. Bosco, Matthew J. LaVoie, Gregory A. Petsko, Dagmar Ringe
Cold Spring Harbor Perspectives in Biology · 2011 · ▲ 65 citations
Abstract
Parkinson's disease (PD) is a movement disorder that afflicts over one million in the U.S.; amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) is less prevalent but also has a high incidence.The two disorders sometimes present together, making a comparative study of interest.Both ALS and PD are neurodegenerative diseases, and are characterized by the presence of intraneuronal inclusions; however, different classes of neurons are affected and the primary protein in the inclusions differs between the diseases, and in some cases is different in distinct forms of the same disease.These observations might suggest that the more general approach of proteostasis(definition) pathway alteration would be a powerful one in treating these disorders.Examining results from human genetics and studies in model organisms, as well as from biochemical and biophysical characterization of the proteins involved in both diseases, we find that most instances of PD can be considered as arising from the misfolding, and self-association to a toxic species, of the small neuronal protein asynuclein, and that proteostasis strategies are likely to be of value for this disorder.For ALS, the situation is much more complex and less clear-cut; the available data are most consistent with a view that ALS may actually be a family of disorders, presenting similarly but arising from distinct and nonoverlapping causes, including mislocalization of some properly folded proteins and derangement of RNA quality control pathways.Applying proteostasis approaches to this disease may require rethinking or broadening the concept of what proteostasis means. INTRODUCTION: NEUROLOGIC DISORDERS OF MOVEMENTM ore than two million Americans are believed to suffer from some form of neurodegenerative movement disorder, the total cost of which is estimated to exceed $10 billion annually.Because no society on earth is spared the effects of these crippling diseases, the figures for other countries are similar, adjusted for population differences.The neurodegenerative
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1101/cshperspect.a007500
- Canonical
- link ↗
- Fetched
- 2026-09-27 MST
Cite this
APA
Bosco, D.A., LaVoie, M.J., Petsko, G.A., & Ringe, D. (2011). Proteostasis and Movement Disorders: Parkinson's Disease and Amyotrophic Lateral Sclerosis. <em>Cold Spring Harbor Perspectives in Biology</em>. https://doi.org/10.1101/cshperspect.a007500
Vancouver
Bosco DA, LaVoie MJ, Petsko GA, Ringe D. Proteostasis and Movement Disorders: Parkinson's Disease and Amyotrophic Lateral Sclerosis. Cold Spring Harbor Perspectives in Biology. 2011. doi:10.1101/cshperspect.a007500.
BibTeX
@unpublished{daryl2011Proteo,
title = {Proteostasis and Movement Disorders: Parkinson's Disease and Amyotrophic Lateral Sclerosis},
author = {Daryl A. Bosco and Matthew J. LaVoie and Gregory A. Petsko and Dagmar Ringe},
journal = {Cold Spring Harbor Perspectives in Biology},
year = {2011},
doi = {10.1101/cshperspect.a007500},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Frontiers in Aging Neuroscience 2022
Open access · CC-BY
Aged Microglia in Neurodegenerative Diseases: Microglia Lifespan and Culture Methods
Frontiers in Molecular Neuroscience 2020
Open access · CC-BY
Therapeutic Approaches Targeting Protein Aggregation in Amyotrophic Lateral Sclerosis
British Journal of Pharmacology 2023
Preprint · OA
Hydrogen sulfide signalling in neurodegenerative diseases
Nature Communications 2015
Open access · CC-BY
The transcriptional landscape of age in human peripheral blood
TSpace (University of Toronto) 2008
Preprint · OA
Role of small ubiquitin-like modifiers (SUMO) in neurodegeneration and Alzheimer's disease
Alzheimer s & Dementia 2025
Open access · CC-BY